Equity Overview
Price & Market Data
Price: $2.70
Daily Change: $0.00 / 0.00%
Daily Range: $2.15 - $2.75
Market Cap: $194,974,448
Daily Volume: 747,611
Performance Metrics
1 Week: 5.88%
1 Month: -18.43%
3 Months: 27.96%
6 Months: 54.29%
1 Year: 150.0%
YTD: 27.96%
Company Details
Employees: 61
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.